Testing sulbactam-durlobactam for children with ABC infection
Treatments studied
Part of Infections clinical trials.
This trial tests a new combination of antibiotics (sulbactam-durlobactam) for children with a serious infection caused by Acinetobacter bacteria. The goal is to see if this treatment is safe and works well for kids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 7 days old and under 18 years old and be in the hospital.
- Your child must have a confirmed or suspected ABC infection that needs IV antibiotics.
- Your child should not have a history of serious allergic reaction to penicillin-like antibiotics.
- Your child should not be pregnant, breastfeeding, or planning pregnancy (if applicable).
- Your child must have blood tests showing their liver and kidneys are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how safe sulbactam-durlobactam (a combination antibiotic) is in adults with a serious infection caused by ABC bacteria, especially looking for allergic reactions. If you are already getting this antibiotic as part of your care, you may be able to join.
This study tests a new antibiotic called aztreonam-avibactam (ATM-AVI) for treating serious bacterial infections in hospitalized babies under 9 months old. The goal is to see if it's safe and works well.
This study tracks hospitalized patients receiving a specific antibiotic combination (sulbactam-durlobactam) to treat a serious, hard-to-treat bacterial infection called CRAB. Researchers want to understand how well this treatment works in real-world hospital settings.
This trial tests two different antibiotic combinations (ampicillin/sulbactam and cefoperazone/sulbactam) to see which works better against a type of bacteria (Acinetobacter baumannii) that is resistant to many other drugs. It is for critically ill patients with signs of sepsis.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This trial tests a new combination of antibiotics (Arm D) against the standard treatment for people with a difficult-to-treat lung infection called Mycobacterium abscessus. It is for adults and teens aged 12 and older, including those with cystic fibrosis.
Hear when a new Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.